Zejula Shows Ability to Treat Range of Advanced Ovarian Cancers in Phase 2 Trial

Zejula Shows Ability to Treat Range of Advanced Ovarian Cancers in Phase 2 Trial
Zejula (niraparib) showed an ability to treat people with recurrent and heavily treated ovarian cancer, particularly those with mutations in DNA repairing genes, results of a Phase 2 trial show. Tesaro’s Zejula is an orally active PARP inhibitor, a class of drugs used for treating cancer in some women who have mutations in BRCA genes. The treatment

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *